Des-γ-carboxyl prothrombin is associated with tumor angiogenesis in hepatocellular carcinoma

Journal of Gastroenterology and Hepatology (Australia)

Volumn 27, Issue 10, 2012, Pages 1602-1608

  Matsubara, Minoru ^a   Shiraha, Hidenori ^a   Kataoka, Jyunro ^a   Iwamuro, Masaya ^a   Horiguchi, Shigeru ^a   Nishina, Shin Ichi ^a   Takaoka, Nobuyuki ^a   Uemura, Masayuki ^a   Takaki, Akinobu ^a   Nakamura, Shinichiro ^a   Kobayashi, Yoshiyuki ^a   Nouso, Kazuhiro ^a   Yamamoto, Kazuhide ^a  

^a OKAYAMA UNIVERSITY   (Japan)

Author keywords

Des carboxyl prothrombin; Hepatocellular carcinoma; Intratumoral microvessel density; Kinase insert domain receptor

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA FETOPROTEIN; ASPARTATE AMINOTRANSFERASE; DES GAMMA CARBOXYL PROTHROMBIN; PROTHROMBIN; UNCLASSIFIED DRUG;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANGIOGENESIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD VESSEL PARAMETERS; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MICROVESSEL DENSITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TUMOR DIFFERENTIATION; TUMOR VASCULARIZATION; TUMOR VOLUME;

EID: 84866550659     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2012.07173.x     Document Type: Article

References (42)

1. Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture. Eur. J. Cancer 2001; 37: S4-66.
2. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132: 2557-76.
3. Llovet JM. Updated treatment approach to hepatocellular carcinoma. J. Gastroenterol. 2005; 40: 225-35.
4. Bruix J, Sala M, Llovet JM. Chemoembolization for hepatocellular carcinoma. Gastroenterology 2004; 127: S179-188.
5. Gish RG, Marrero JA, Benson AB. A multidisciplinary approach to the management of hepatocellular carcinoma. Gastroenterol. Hepatol. (N. Y.) 2010; 6: 1-16.
6. Llovet JM, Ricci S, Mazzaferro V etal. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 2008; 359: 378-90.
7. Gomaa AI, Khan SA, Leen EL, Waked I, Taylor-Robinson SD. Diagnosis of hepatocellular carcinoma. World J. Gastroenterol. 2009; 15: 1301-14.
8. Park YN, Kim YB, Yang KM, Park C. Increased expression of vascular endothelial growth factor and angiogenesis in the early stage of multistep hepatocarcinogenesis. Arch. Pathol. Lab. Med. 2000; 124: 1061-5.
9. Roncalli M, Roz E, Coggi G etal. The vascular profile of regenerative and dysplastic nodules of the cirrhotic liver: implications for diagnosis and classification. Hepatology 1999; 30: 1174-8.
10. Poon RT, Ng IO, Lau C etal. Serum vascular endothelial growth factor predicts venous invasion in hepatocellular carcinoma: a prospective study. Ann. Surg. 2001; 233: 227-35.
11. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407: 249-57.
12. Yao DF, Wu XH, Zhu Y etal. Quantitative analysis of vascular endothelial growth factor, microvascular density and their clinicopathologic features in human hepatocellular carcinoma. Hepatobiliary Pancreat. Dis. Int. 2005; 4: 220-6.
13. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86: 353-64.
14. Fujii T, Nomoto S, Koshikawa K etal. Overexpression of pituitary tumor transforming gene 1 in HCC is associated with angiogenesis and poor prognosis. Hepatology 2006; 43: 1267-75.
15. Pang R, Poon RT. Angiogenesis and antiangiogenic therapy in hepatocellular carcinoma. Cancer Lett. 2006; 242: 151-67.
16. Mise M, Arii S, Higashituji H etal. Clinical significance of vascular endothelial growth factor and basic fibroblast growth factor gene expression in liver tumor. Hepatology 1996; 23: 455-64.
17. Li Q, Xu B, Fu L, Hao XS. Correlation of four vascular specific growth factors with carcinogenesis and portal vein tumor thrombus formation in human hepatocellular carcinoma. J. Exp. Clin. Cancer Res. 2006; 25: 403-9.
18. Uematsu S, Higashi T, Nouso K etal. Altered expression of vascular endothelial growth factor, fibroblast growth factor-2 and endostatin in patients with hepatocellular carcinoma. J. Gastroenterol. Hepatol. 2005; 20: 583-8.
19. Stock P, Monga D, Tan X, Micsenyi A, Loizos N, Monga SP. Platelet-derived growth factor receptor-alpha: a novel therapeutic target in human hepatocellular cancer. Mol. Cancer Ther. 2007; 6: 1932-41.
20. Tanaka S, Mori M, Sakamoto Y, Makuuchi M, Sugimachi K, Wands JR. Biologic significance of angiopoietin-2 expression in human hepatocellular carcinoma. J. Clin. Invest. 1999; 103: 341-5.
21. Yamamoto K, Imamura H, Matsuyama Y etal. Significance of alpha-fetoprotein and des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma undergoing hepatectomy. Ann. Surg. Oncol. 2009; 16: 2795-804.
22. Miyaaki H, Nakashima O, Kurogi M, Eguchi K, Kojiro M. Lens culinaris agglutinin-reactive alpha-fetoprotein and protein induced by vitamin K absence II are potential indicators of a poor prognosis: a histopathological study of surgically resected hepatocellular carcinoma. J. Gastroenterol. 2007; 42: 962-8.
23. Nagaoka S, Yatsuhashi H, Hamada H etal. The des-gamma-carboxy prothrombin index is a new prognostic indicator for hepatocellular carcinoma. Cancer 2003; 98: 2671-7.
24. Kobayashi M, Ikeda K, Kawamura Y etal. High serum des-gamma-carboxy prothrombin level predicts poor prognosis after radiofrequency ablation of hepatocellular carcinoma. Cancer 2009; 115: 571-80.
25. Hagiwara S, Kudo M, Kawasaki T etal. Prognostic factors for portal venous invasion in patients with hepatocellular carcinoma. J. Gastroenterol. 2006; 41: 1214-19.
26. Koike Y, Shiratori Y, Sato S etal. Des-gamma-carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma: a prospective analysis of 227 patients. Cancer 2001; 91: 561-9.
27. Fujikawa T, Shiraha H, Ueda N etal. Des-gamma-carboxyl prothrombin-promoted vascular endothelial cell proliferation and migration. J. Biol. Chem. 2007; 282: 8741-8.
28. Wang SB, Cheng YN, Cui SX etal. Des-gamma-carboxy prothrombin stimulates human vascular endothelial cell growth and migration. Clin. Exp. Metastasis 2009; 26: 469-77.
29. Gao FJ, Cui SX, Chen MH etal. Des-gamma-carboxy prothrombin increases the expression of angiogenic factors in human hepatocellular carcinoma cells. Life Sci. 2008; 83: 815-20.
30. Kogita S, Imai Y, Okada M etal. Gd-EOB-DTPA-enhanced magnetic resonance images of hepatocellular carcinoma: correlation with histological grading and portal blood flow. Eur. Radiol. 2010; 20: 2405-13.
31. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-36.
32. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-2.
33. Guo J, Higashi K, Ueda Y etal. Microvessel density: correlation with 18F-FDG uptake and prognostic impact in lung adenocarcinomas. J. Nucl. Med. 2006; 47: 419-25.
34. Ueda N, Shiraha H, Fujikawa T etal. Exon 2 deletion splice variant of gamma-glutamyl carboxylase causes des-gamma-carboxy prothrombin production in hepatocellular carcinoma cell lines. Mol. Oncol. 2008; 2: 241-9.
35. Donovan D, Brown NJ, Bishop ET, Lewis CE. Comparison of three in vitro human "angiogenesis" assays with capillaries formed in vivo. Angiogenesis 2001; 4: 113-21.
36. Xiao EH, Guo D, Bian DJ. Effect of preoperative transcatheter arterial chemoembolization on angiogenesis of hepatocellular carcinoma cells. World J. Gastroenterol. 2009; 15: 4582-6.
37. Golfieri R, Renzulli M, Lucidi V, Corcioni B, Trevisani F, Bolondi L. Contribution of the hepatobiliary phase of Gd-EOB-DTPA-enhanced MRI to Dynamic MRI in the detection of hypovascular small (≤2cm) HCC in cirrhosis. Eur. Radiol. 2011; 21: 1233-42.
38. Suzuki M, Shiraha H, Fujikawa T etal. Des-gamma-carboxy prothrombin is a potential autologous growth factor for hepatocellular carcinoma. J. Biol. Chem. 2005; 280: 6409-15.
39. Yoon SH, Lee JM, So YH etal. Multiphasic MDCT enhancement pattern of hepatocellular carcinoma smaller than 3cm in diameter: tumor size and cellular differentiation. AJR Am. J. Roentgenol. 2009; 193: W482-9.
40. Sun T, Zhao N, Zhao XL etal. Expression and functional significance of Twist1 in hepatocellular carcinoma: its role in vasculogenic mimicry. Hepatology 2010; 51: 545-56.
41. Uehara S, Gotoh K, Handa H, Honjo K, Hirayama A. Process of carboxylation of glutamic acid residues in the gla domain of human des-gamma-carboxyprothrombin. Clin. Chim. Acta 1999; 289: 33-44.
42. Poon RT, Ng IO, Lau C etal. Tumor microvessel density as a predictor of recurrence after resection of hepatocellular carcinoma: a prospective study. J. Clin. Oncol. 2002; 20: 1775-85.